Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2000
Salvati P.; Caccia C.; Maj R.; Musanti R.; Lamberti E.; Calabresi M.; Benatti L.; Fariello R.G.
NW-1048 is a Novel, Reversible and Selective MAO-B Inhibitor with Neuroprotective Effects in a Model of Parkinson's Disease.
30th Neuroscience Conference New Orleans, 2000
Faravelli L.; Maj R.; Veneroni O.; Fariello R.G.; Benatti L.; Salvati P.;
NW-1029 Is a Novel Na+Channel Blocker with Analgesic Activity in Animal Models.
Soc. for Neuroscience, Abs,26 (1): 1218, 2000
Marzo A.; Dal Bo L.; Crivelli F.; Ceppi Monti N.; Ismaili S.; Fariello R.G.; Uhr M.R.;
Pharmacokinetics, Pharmacodynamics and Tolerability of NW-1015, a New Anticonvulsant Agent.
5th Eilat Conference on New Antiepileptic Drugs, 2000
Fariello R.G.; Maj R.; Caccia C.; Benatti L.; Salvati P.
NW-1015 a Novel Potential Antiepileptic Drug: Preclinical and Early Clinical Development.
5th Eilat Conference on New Antiepileptic Drugs, 2000
Fariello R.G.; Maj R.; Marrari P.; Pevarello P.; Beard D.; Algate C.; Post C.; Salvati P.
Acute Behavioral and EEG Effects of NW-1015 on Electrically-Induced Afterdischarge in Conscious Monkeys.
Epilepsy Res., 39: 37-46, 2000
Schafer M.; Schwaeble W.J.; Post C.; Salvati P.; Calabresi M.; Sim R.B.; Petry F.; Loos M.; Weihe E.
Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia.
Journal Immunology, 164, 2000